| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Chlorhexidine diacetate targets microbial cell membranes. Its mechanism involves non-specific binding to membrane phospholipids, leading to structural disruption and leakage of cellular contents. At low concentrations, it exerts a bacteriostatic effect by increasing membrane permeability; at higher concentrations, it causes lytic effects. The compound also causes precipitation of intracellular substances.
|
|---|---|
| ln Vitro |
Chlorhexidine diacetate demonstrates potent in vitro broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria. Its effectiveness is attributed to its ability to disrupt microbial cell membranes, leading to cell death. The compound's antimicrobial activity is concentration-dependent, with low concentrations causing bacteriostatic effects and higher concentrations causing bactericidal effects.
|
| ln Vivo |
In vivo activity of chlorhexidine diacetate has been demonstrated in clinical and veterinary applications as an antiseptic and disinfectant. It is used for skin disinfection, wound cleaning, oral hygiene, and surgical site preparation. The compound's broad-spectrum activity and persistence make it effective for infection control.
|
| Enzyme Assay |
In vitro antimicrobial assays for chlorhexidine diacetate involve testing its effectiveness against various bacterial and fungal strains using standard susceptibility testing methods. The minimum inhibitory concentration (MIC) is determined against Gram-positive and Gram-negative bacteria. Membrane disruption can be assessed using membrane permeability assays.
|
| Cell Assay |
In vitro cellular assays for chlorhexidine diacetate are not typically performed, as it is an antimicrobial agent used in disinfection. Its effects on bacterial cells can be assessed by measuring cell viability, membrane integrity, and leakage of intracellular contents.
|
| Animal Protocol |
In vivo animal experiments for chlorhexidine diacetate have been conducted in models of wound infection, oral hygiene, and surgical site infection. The compound is applied topically, and efficacy is evaluated by measuring bacterial load reduction and clinical outcomes. Its safety and efficacy in animals support its use in veterinary medicine.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for chlorhexidine diacetate indicate that it is poorly absorbed from the gastrointestinal tract and is primarily used topically. When applied to skin or mucous membranes, it binds to the stratum corneum and provides persistent antimicrobial activity. Its systemic absorption is minimal, contributing to its favorable safety profile.
|
| Toxicity/Toxicokinetics |
Toxicity Data
LC50 (Rat) = 300 mg/m³ Toxicological data for chlorhexidine diacetate indicate that it is generally safe for topical use. However, it can cause skin irritation, allergic reactions, and mucosal damage at high concentrations. It should not be used in the eyes or in contact with the middle ear. The compound is for topical use only. |
| References |
[1]. Sanchez IR, et al. Chlorhexidine diacetate and povidone-iodine cytotoxicity to canine embryonic fibroblasts and Staphylococcus aureus. Vet Surg. 1988;17(4):182-185.
|
| Additional Infomation |
Chlorhexidine acetate is the acetate salt of chlorhexidine. It is a disinfectant used for bacterial control in hospitals, agriculture, and home environments. It has antibacterial, anti-infective, antifungal, and antifouling properties. Its main component is chlorhexidine. It is a disinfectant and a topical anti-infective agent, and can also be used as a mouthwash to prevent dental plaque.
Chlorhexidine diacetate (CAS#: 56-95-1) has the molecular formula C22H30Cl2N10·2C2H4O2 and a molecular weight of 625.55. It is a synthetic bisbiguanide with broad-spectrum antimicrobial properties. Chlorhexidine binds to microbial cell membranes, destroying membrane structure and inducing leakage of cell contents. It is extensively used as an antiseptic and disinfectant. |
| Molecular Formula |
C26H38CL2N10O4
|
|---|---|
| Molecular Weight |
625.55
|
| Exact Mass |
624.245
|
| CAS # |
56-95-1
|
| Related CAS # |
Chlorhexidine (digluconate);18472-51-0;Chlorhexidine dihydrochloride;3697-42-5;Chlorhexidine;55-56-1;Chlorhexidine acetate hydrate;206986-79-0
|
| PubChem CID |
9562059
|
| Appearance |
Typically exists as solid at room temperature
|
| Boiling Point |
699.3ºC at 760mmHg
|
| Melting Point |
153-156ºC
|
| Flash Point |
376.7ºC
|
| LogP |
6.374
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
42
|
| Complexity |
680
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C([H])=C([H])C(=C([H])C=1[H])N([H])/C(/N([H])[H])=N/C(/N([H])[H])=N/C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N=C(\N([H])[H])/N([H])C1C([H])=C([H])C(=C([H])C=1[H])Cl.O([H])C(C([H])([H])[H])=O.O([H])C(C([H])([H])[H])=O
|
| InChi Key |
WDRFFJWBUDTUCA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H30Cl2N10.2C2H4O2/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18;2*1-2(3)4/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34);2*1H3,(H,3,4)
|
| Chemical Name |
acetic acid;(1E)-2-[6-[[amino-[(E)-[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : 55 mg/mL (87.92 mM)
H2O : 20 mg/mL (31.97 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.00 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5986 mL | 7.9930 mL | 15.9859 mL | |
| 5 mM | 0.3197 mL | 1.5986 mL | 3.1972 mL | |
| 10 mM | 0.1599 mL | 0.7993 mL | 1.5986 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
